Positive high-level results from the phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination ...

Breztri Aerosphere, a triple inhaled therapy, met its primary endpoint of lung function improvement in adults and adolescents ...

KALOS and LOGOS included approximately 4,400 randomized patients. Also Read: Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis The trials met all ...

Q1 2026 Earnings Conference Call May 21, 2025 5:00 PM ETCompany ParticipantsJimmy Sexton - Head of IRSridhar Ramaswamy - ...

AstraZeneca (AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said a more favorable corporate tax credit could motivate ...

AstraZeneca has announced positive high-level results from its Phase III KALOS and LOGOS trials, showing significant promise ...

Revenues came in at $13.59 billion, missing Wall Street's estimates of $13.76 billion. In this photo illustration, the AstraZeneca logo is displayed on a smartphone screen with a stock market chart in ...

Soon, Maryland will be home to one of the largest facilities dedicated exclusively to cell therapy at AstraZeneca's Rockville ... the Funniest Reaction to Her Logo Three vs. Brazil ...

A day of expert panels and prestigious honours for the UK's most impactful health innovations LONDON, May 8, 2025 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated ...

AstraZeneca’s triple-combination therapy Breztri Aerosphere ... in the Phase III KALOS (NCT04609878) and LOGOS (NCT04609904) trials in patients with uncontrolled asthma. KALOS and LOGOS were ...